Skip to main content

Advertisement

SpringerLink
Log in

Intestinal Barrier and Gut Microbiota in Patients with Overlapping Irritable Bowel Syndrome and Functional Dyspepsia

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Disturbances in the intestinal barrier and gut dysbiosis have been observed in patients with functional bowel diseases.

Aims

To investigate the correlation between biomarkers of intestinal barrier disorders at different layers and the severity of symptoms in patients with overlapping diarrhea-predominant irritable bowel syndrome and functional dyspepsia (IDFO), as well as with gut microbiota taxa.

Methods

This study included 45 patients with IDFO and 16 healthy controls. Endoscopy with biopsy of the duodenum and sigmoid colon (SC) was performed to count intraepithelial lymphocytes (IELs) and mucosal eosinophils (subepithelial layer), assess fatty acid binding protein (FABP; epithelial layer) level, and stain for mucin-2 (MUC-2; pre-epithelial layer). Composition of the gut microbiota was evaluated using 16S rRNA gene sequencing.

Results

Patients with IDFO exhibited an increase in biomarkers of intestinal barrier disorders at all layers studied. IEL count in the duodenum was correlated with the severity of bloating (r = 0.336; p = 0.024) and, in the SC, was correlated with tenesmus severity (r = 0.303; p = 0.042). FABP-1 level in the SC was correlated with the severity of diarrhea (r = 0.577; p = 0.001), and FABP-5 concentration in the SC was correlated with abdominal distension (r = 0.477; p = 0.010). MUC-2 concentration in the duodenum was correlated with the severity of heartburn (r = 0.572; p = 0.025) and burning sensation in the epigastrium (r = 0.518; p = 0.048). All biomarkers of intestinal barrier permeability were correlated with the abundance of some gut microbiota taxa.

Conclusion

Patients with IDFO exhibited disrupted intestinal barrier function in all layers, which was associated with clinical symptom severity and changes in the gut microbiota.

Graphical Abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

The datasets used can be available from the corresponding author on reasonable request.

References

  1. Lacy BE, Mearin F, Chang L, Chey WD et al. Bowel disorders. Gastroenterology. 2016;150:1393–1407. https://doi.org/10.1053/j.gastro.2016.02.031.

    Article  Google Scholar 

  2. Ivashkin VT, Maev IV, Shelygin YuA et al. Diagnosis and treatment of irritable bowel syndrome: clinical recommendations of the Russian gastroenterological association and association of coloproctologists of Russia. Russ J Gastroenterol Hepatol Coloproctol. 2021;31:74–95. https://doi.org/10.22416/1382-4376-2021-31-5-74-95.

    Article  Google Scholar 

  3. Enck P, Azpiroz F, Boeckxstaens G et al. Functional dyspepsia. Nat Rev Dis Primers. 2017;3:17081. https://doi.org/10.1038/nrdp.2017.81.

    Article  PubMed  Google Scholar 

  4. Scaldaferri F, Pizzoferrato M, Gerardi V, Lopetuso L, Gasbarrini A. The gut barrier: new acquisitions and therapeutic approaches. J Clin Gastroenterol. 2012;46:S12–S17. https://doi.org/10.1097/MCG.0b013e31826ae849.

    Article  CAS  PubMed  Google Scholar 

  5. Schneeberger EE, Lynch RD. The tight junction: a multifunctional complex. Am J Physiol Cell Physiol. 2004;286:C1213–C1228. https://doi.org/10.1152/ajpcell.00558.2003.

    Article  CAS  PubMed  Google Scholar 

  6. Fukui H. Increased intestinal permeability and decreased barrier function: does it really influence the risk of inflammation? Inflamm Intest Dis. 2016;1:135–145. https://doi.org/10.1159/000447252.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Salim SY, Söderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17:362–381. https://doi.org/10.1002/ibd.21403.

    Article  PubMed  Google Scholar 

  8. Jakobsson HE, Rodríguez-Piñeiro AM, Schütte A et al. The composition of the gut microbiota shapes the colon mucus barrier. EMBO Rep. 2015;16:164–177. https://doi.org/10.15252/embr.201439263.

    Article  CAS  PubMed  Google Scholar 

  9. Groschwitz KR, Hogan SP. Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol. 2009;124:3–20. https://doi.org/10.1016/j.jaci.2009.05.038.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Simanenkov VI, Maev IV, Tkacheva ON et al. Increased epithelial permeability syndrome in clinical practice multidisciplinary national consensus. Cardiovasc Ther Prev. 2021;20:2758. https://doi.org/10.15829/1728-8800-2021-2758.

    Article  Google Scholar 

  11. Kovaleva AL, Poluektova EA, Shifrin OS. Intestinal barrier, intestinal permeability, nonspecific inflammation and their role in forming functional diseases of gastrointestinal tract. Russ J Gastroenterol Hepatol Coloproctol. 2020;30:52–59. https://doi.org/10.22416/1382-4376-2020-30-4-52-59.

    Article  Google Scholar 

  12. Schoultz I, Keita ÅV. The Intestinal barrier and current techniques for the assessment of gut permeability. Cells. 2020;9:1909. https://doi.org/10.3390/cells9081909.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Sinagra E, Pompei G, Tomasello G et al. Inflammation in irritable bowel syndrome: myth or new treatment target? World J Gastroenterol. 2016;22:2242–2255. https://doi.org/10.3748/wjg.v22.i7.2242.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Wibowo AA, Pardjianto B, Sumitro SB, Kania N, Handono K. Decreased expression of MUC2 due to a decrease in the expression of lectins and apoptotic defects in colitis patients. Biochem Biophys Rep. 2019;19:100655. https://doi.org/10.1016/j.bbrep.2019.100655.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Du L, Chen B, Kim JJ, Chen X, Dai N. Micro-inflammation in functional dyspepsia: a systematic review and meta-analysis. Neurogastroenterol Motil. 2018;30:e13304. https://doi.org/10.1111/nmo.13304.

    Article  CAS  PubMed  Google Scholar 

  16. Taki M, Oshima T, Li M et al. Duodenal low-grade inflammation and expression of tight junction proteins in functional dyspepsia. Neurogastroenterol Motil. 2019;31:e13576. https://doi.org/10.1111/nmo.13576.

    Article  PubMed  Google Scholar 

  17. Lee JY, Kim N, Choi YJ et al. Expression of tight junction proteins according to functional dyspepsia subtype and sex. J Neurogastroenterol Motil. 2020;26:248–258. https://doi.org/10.5056/jnm19208.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Ivashkin VT, Mayev IV, Sheptulin AA et al. Diagnosis and treatment of the functional dyspepsia: clinical guidelines of the Russian Gastroenterological Association. Russ J Gastroenterol Hepatol Coloproctol\. 2017;27:50–61. https://doi.org/10.22416/1382-4376-2017-27-1-50-61.

    Article  Google Scholar 

  19. Humes DJ. Changing epidemiology: does it increase our understanding? Dig Dis. 2012;30:6–11. https://doi.org/10.1159/000335692.

    Article  PubMed  Google Scholar 

  20. Ivashkin VT, Sheptulin AA, Poluektova EA et al. Opportunities of 7x7 Scale (7 symptoms per 7 Days) to evaluate dynamics in symptoms of functional dyspepsia and irritable bowel syndrome. Russ J Gastroenterol Hepatol Coloproctol. 2016;26:24–33. https://doi.org/10.22416/1382-4376-2016-26-3-24-33.

    Article  Google Scholar 

  21. Revicki DA, Wood M, Wiklund I, Crawley J. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease. Qual Life Res. 1998;7:75–83. https://doi.org/10.1023/a:1008841022998.

    Article  CAS  PubMed  Google Scholar 

  22. Jung HK, Talley NJ. Role of the duodenum in the pathogenesis of functional dyspepsia: a paradigm shift. J Neurogastroenterol Motil. 2018;24:345–354. https://doi.org/10.5056/jnm18060.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Lacy BE, Cangemi DJ. Updates in functional dyspepsia and bloating. Curr Opin Gastroenterol. 2022;38:613–619. https://doi.org/10.1097/MOG.0000000000000882.

    Article  PubMed  Google Scholar 

  24. Adriaanse MP, Tack GJ, Passos VL et al. Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies. Aliment Pharmacol Ther. 2013;37:482–490. https://doi.org/10.1111/apt.12194.

    Article  CAS  PubMed  Google Scholar 

  25. Adriaanse MPM, Mubarak A, Riedl RG et al. Progress towards non-invasive diagnosis and follow-up of celiac disease in children; a prospective multicentre study to the usefulness of plasma I-FABP. Sci Rep. 2017;7:8671. https://doi.org/10.1038/s41598-017-07242-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Shi H, Wan J, Liu W, Su B. An analysis for the clinical difference between post infectious irritable bowel syndrome and non post infectious irritable bowel syndrome. Zhonghua Nei Ke Za Zhi. 2015;54:326–329.

    CAS  PubMed  Google Scholar 

  27. Li B, Reynolds JM, Stout RD, Bernlohr DA, Suttles J. Regulation of Th17 differentiation by epidermal fatty acid-binding protein. J Immunol. 2009;182:7625–7633. https://doi.org/10.4049/jimmunol.0804192.

    Article  CAS  PubMed  Google Scholar 

  28. Grondin JA, Kwon YH, Far PM, Haq S, Khan WI. Mucins in intestinal mucosal defense and inflammation: learning from clinical and experimental studies. Front Immunol. 2020;11:2054. https://doi.org/10.3389/fimmu.2020.02054.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Ivashkin VT, Trukhmanov AS, Gonik MI. Using rebamipide in treating gastroesophageal reflux disease. Therapeutic Archive. 2020;92:98–104. https://doi.org/10.26442/00403660.2020.04.000568.

    Article  CAS  Google Scholar 

  30. Arakawa T, Higuchi K, Fujiwara Y et al. 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig Dis Sci. 2005;50:S3–S11. https://doi.org/10.1007/s10620-005-2800-9.

    Article  CAS  PubMed  Google Scholar 

  31. Kleine A, Kluge S, Peskar BM. Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats. Dig Dis Sci. 1993;38:1441–1449. https://doi.org/10.1007/BF01308601.

    Article  CAS  PubMed  Google Scholar 

  32. Gweon TG, Park JH, Kim BW et al. Additive Effects of rebamipide plus proton pump inhibitors on the expression of tight junction proteins in a rat model of gastro-esophageal reflux disease. Gut Liver. 2018;12:46–50. https://doi.org/10.5009/gnl17078.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

No funding.

Author information

Authors and Affiliations

  1. Sechenov University, Moscow, Russia, 119435

    Aleksandra Kovaleva, Elena Poluektova, Roman Maslennikov, Anna Karchevskaya, Oleg Shifrin, Andrey Kiryukhin, Aleksandr Tertychnyy, Olga Lobanova & Vladimir Ivashkin

  2. A.N. Bach Institute of Biochemistry, Leninsky Prospekt, 33, Bld. 2, Moscow, Russia, 119071

    Leonid Kovalev & Marina Kovaleva

  3. Engelhardt Institute of Molecular Biology, Vavilova St., 32, Bld. 1, Moscow, Russia, 119991

    Anna Kudryavtseva & George Krasnov

Authors
  1. Aleksandra Kovaleva
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elena Poluektova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roman Maslennikov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anna Karchevskaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Oleg Shifrin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Andrey Kiryukhin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Aleksandr Tertychnyy
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Leonid Kovalev
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Marina Kovaleva
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Olga Lobanova
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Anna Kudryavtseva
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. George Krasnov
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Vladimir Ivashkin
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by AK, RM, AT, AK, and GK. The first draft of the manuscript was written by Aleksandra Kovaleva and Roman Maslennikov and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Roman Maslennikov.

Ethics declarations

Conflict of interest

There is no conflict of interest.

Ethical approval and consent to participate

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Local Ethics Committee.

Consent for publication

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kovaleva, A., Poluektova, E., Maslennikov, R. et al. Intestinal Barrier and Gut Microbiota in Patients with Overlapping Irritable Bowel Syndrome and Functional Dyspepsia. Dig Dis Sci 68, 4166–4174 (2023). https://doi.org/10.1007/s10620-023-08117-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-023-08117-7

Keywords

Search

Navigation